This clinical scenario showcases a formidable, real-world surgical challenge: a young man with massive, chemo-resistant retroperitoneal teratoma, significant hydronephrosis, an IVC filter, and extensive thoracic disease, made even higher stakes by his status as a Jehovah’s Witness. Drs. Adra, Bagrodia, and Matulewics dive into how experts weigh resectability, sequencing of therapy, and meticulous preoperative planning when blood loss and major vascular involvement are real risks. Viewers get an inside look at the technical complexity of the operation and how a carefully coordinated, multidisciplinary strategy ultimately achieved a disease-free outcome. It’s a vivid illustration of how high-level surgical judgment and planning can turn an almost “unresectable” situation into a success.
Contributors:
Dr. Nabil Adra is a hematologist and Associate Professor of Clinical Medicine and Urology at Indiana University Health in Indianapolis, Indiana.
Dr. Aditya Bagrodia is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.
Dr. Richard Matulewicz is a urologic oncologist and surgeon at Memorial Sloan Kettering Cancer Center in New York City.
